The Ipsos Almanac
We see with our mind, not just with our eyes
This white paper argues that it is essential to link responses to a product’s appearance back to the visual features that trigger them.
Ipsos Update - May 2019
May’s edition presents Ipsos’ latest research and thinking on topics including climate change, our ‘vices’ – or morally questionable behaviours, driverless cars, shopper technology, creative advertising and trends in MENA.
A public dialogue on genomic medicine: time for a new social contract?
Genomic medicine will change the relationship between the NHS and the people who use it, according to a major new public dialogue project by Ipsos.
Employers’ motivations and practices: A study of the use of occupational health services
Ipsos was commissioned by the Work and Health Unit (WHU) to undertake qualitative research with employers in Great Britain with two or more employees, to explore their practices and motivations for using occupational health services.
Driverless Futures?
Self-driving cars create both opportunities and uncertainties for the public. How can we find out what the public thinks about a technology that doesn’t yet exist?
Let’s Get Phygital
View our on demand webinar for a demonstration of Simstore, Ipsos’ virtual shopping solution.
Ipsos Creative Excellence's new video sparks Creativity
Creativity is Business. Ipsos’ Creative Excellence bringing back the magic.
Concept testing the migration of tax credits customers to Universal Credit
This report presents the findings from the qualitative research carried out by Ipsos on behalf of HMRC. The report explores how tax credit customers would react to a possible managed migration journey and what support they would potentially need.
Selling Creative Research Short?
How creative research can help measure and fuel long-term campaign effects
Public awareness and knowledge of genomics/ genomic medicines is low
Ipsos was commissioned by Genomics England to conduct a short poll to investigate the public’s awareness of issues around genomics and genomic medicines.